Want to see AU:IMU full AI Analyst Report?

Imugene (IMU) Price & Analysis

151 Followers

IMU Stock Chart & Stats

AU$0.07

AU$0.00(0.00%)

At close: Jul 27 4:00 PM EDT

AU$0.07

AU$0.00(0.00%)

Day’s Range― - ―

52-Week RangeAU$0.03 - AU$0.43

Previous CloseN/A

Volume4.23M

Average Volume (3M)3.72M

Market Cap

AU$20.33M

Enterprise ValueAU$43.81M

Total Cash (Recent Filing)AU$2.63M

Total Debt (Recent Filing)AU$6.30M

Price to Earnings (P/E)―

Beta2.44

Next Earnings

Mar 03, 2027

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding549,574,700

10 Day Avg. Volume3,342,537

30 Day Avg. Volume3,717,750

Financial Highlights & Ratios

PEG Ratio0.00

Price to Book (P/B)4.16

Price to Sales (P/S)0.00

P/FCF Ratio-0.84

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.03

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Pipeline FocusA focused clinical-stage pipeline gives Imugene a defined strategic direction in cancer immunotherapy. Advancing candidates through preclinical and clinical development can create future partnering or commercial opportunities if programs demonstrate sufficient safety and efficacy.

Multiple Immunotherapy ModalitiesExposure to several immunotherapy approaches provides more than one potential route to clinical and commercial progress. Although development outcomes remain uncertain, a broader modality set can preserve strategic options as evidence emerges across different cancer-treatment mechanisms.

Relatively Low LeverageModest debt reduces the immediate burden of interest and principal obligations while the company funds research and development. This gives Imugene some financial flexibility compared with a similarly loss-making biotech carrying materially higher leverage.

Bears Say

No Current Product RevenueThe absence of current product revenue means Imugene is not yet funding operations through a recurring commercial franchise. Its ability to advance programs therefore depends on financing or future development success, making the business model structurally pre-commercial.

Persistent Cash BurnSustained negative operating and free cash flow requires continuing access to external capital to fund clinical development and corporate expenses. This creates ongoing financing exposure and can constrain program choices if available funding becomes less supportive.

Eroding Financial BaseDeclining equity and assets indicate that historical cash resources are being consumed while the company remains loss-making. A smaller capital cushion increases the consequences of further delays or unsuccessful trials and heightens future dilution or funding risk.

Imugene News

Imugene posts strong new responses in Phase 1b azer-cel trial for B-cell malignancies

An announcement from Imugene ( ($AU:IMU) ) is now available. Imugene has reported new efficacy data from its...

4d ago

Imugene Seeks ASX Quotation for Additional Ordinary Shares

Imugene ( ($AU:IMU) ) has provided an announcement. Imugene Limited has applied for quotation on the ASX of...

9d ago

Imugene Sets 2026 AGM, Flags Governance and Capital Management Resolutions

Imugene ( ($AU:IMU) ) has issued an announcement. Imugene Limited has called its 2026 Annual General Meeting for...

14d ago

Imugene reshapes leadership as it sharpens focus on azer-cel CAR T program

An update from Imugene ( ($AU:IMU) ) is now available. Imugene has appointed physician-scientist Dr John Le Gall...

16d ago

Imugene Posts Strong Early Responses in Azer-cel BTKi Combo Trial

Imugene ( ($AU:IMU) ) has provided an update. Imugene has reported new efficacy data from Cohort 3 of...

18d ago

Imugene Director’s Options Expire, Adjusting Equity Mix Without New Dilution

Imugene ( ($AU:IMU) ) has shared an update. Imugene Limited reported a change in director Jakob Dupont’s interests,...

22d ago

Imugene Seeks ASX Quotation for 15.8 Million New Shares

Imugene ( ($AU:IMU) ) has shared an update. Imugene Limited has applied for quotation of 15,813,253 new ordinary...

1M ago

Imugene Issues 43.4 Million New Shares Under Capital Raising

Imugene ( ($AU:IMU) ) has provided an update. Imugene Limited has issued 43,368,423 fully paid ordinary shares at...

2M ago

Imugene seeks ASX quotation for 15.8 million new shares

An announcement from Imugene ( ($AU:IMU) ) is now available. Imugene Limited has applied to the ASX for...

2M ago

Imugene Director’s Options Lapse Without Exercise

Imugene ( ($AU:IMU) ) has shared an announcement. Imugene Limited has disclosed a change in the interests of...

2M ago

IMU FAQ

What was Imugene’s price range in the past 12 months?

Imugene lowest share price was AU$0.03 and its highest was AU$0.43 in the past 12 months.

What is Imugene’s market cap?

Imugene’s market cap is AU$20.33M.

When is Imugene’s upcoming earnings report date?

Imugene’s upcoming earnings report date is Mar 03, 2027 which is in 131 days.

How were Imugene’s earnings last quarter?

Imugene released its earnings results on Sep 02, 2026. The company reported -AU$0.193 earnings per share for the quarter, missing the consensus estimate of -AU$0.036 by -AU$0.157.

Is Imugene overvalued?

According to Wall Street analysts Imugene’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Imugene pay dividends?

Imugene does not currently pay dividends.

What is Imugene’s EPS estimate?

Imugene’s EPS estimate is -0.03.

How many shares outstanding does Imugene have?

Imugene has 549,574,700 shares outstanding.

What happened to Imugene’s price movement after its last earnings report?

Imugene reported an EPS of -AU$0.193 in its last earnings report, missing expectations of -AU$0.036. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Imugene?

Currently, no hedge funds are holding shares in AU:IMU

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Imugene Stock Smart Score

Neutral

Fundamentals

Return on Equity

-414.10%

Trailing 12-Months

Asset Growth

-70.87%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

Imugene

Imugene Limited, a clinical-stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumours in Australia. Its lead products under development azer-cel, an allogeneic CAR T cell therapy in phase 1 clinical trial targeting relapsed/refractory non-hodgkin lymphoma and b-cell acute lymphoblastic leukemia; CF33 VAXINIA, a combination of genomic sequences from various vaccinia virus strains to generate potent virus in phase 1 clinical trial for mixed advanced solid tumours; and CF33 CD19 chimeric antigen receptor T cells therapies to target solid tumours in phase 1 study. The company also develops CF33 oncolytic virotherapy; HER-VAXX, a B-cell immunotherapy cancer vaccine completed phase 2 clinical trial to target metastatic gastric cancer; HERIZON, which is in Phase 1b/2 study for HER-Vaxx and chemotherapy; PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling in phase 2 clinical trial to target non-small cell lung cancer; and NeoPOLEM in phase 2 study for MSI-high colorectal cancer. Imugene Limited is headquartered in Sydney, Australia.